The entire pharmaceutical sector has surged sharply; what happened?

On Monday, all AH Stocks in the pharmaceutical Sector surged, with innovative drugs performing the strongest. The Yinhua CSI Innovative Drugs Industry ETF collectively rose sharply, driven by three main factors: the relaxation of collective procurement, overseas license authorizations, and improvement in Earnings Reports that will reshape the Industry landscape.

wallstreetcnApr 1 08:38 ET

Introducing two major international capitals, Fosun UnitedHealth is starting a new round of capital increase and share expansion, and after multiple rounds of financing, it will focus on the Fosun ecosystem.

① Planning to introduce two major international capitals: the International Finance Corporation and the Asian Development Bank; ② The total cash investment from investors amounts to 0.81 billion yuan (or the equivalent in USD); ③ Since its establishment, multiple rounds of funding have been obtained through shareholder donations and capital increases.

cls.cnApr 1 08:26 ET

The Social Security Fund's annual report on Hold Positions has been revealed! A total of 52 new stocks entered the top ten circulating Shareholders list, with China Resources Double-Crane Pharmaceutical receiving the most Shareholding increases.

① With the continuous disclosure of the 2024 annual reports of listed companies, the Social Security Fund has newly entered the top ten circulating shareholders list of 52 individual stocks; ② Among them, China Resources Double-Crane Pharmaceutical has the highest number of new holdings by the Social Security Fund, reaching 3; ③ Attached is the list of A-shares where the number of newly added Institutions held by the Social Security Fund in the fourth quarter of 2024 ranks highest (attached table).

cls.cnMar 29 04:55 ET

0.124 billion USD! FOSUN PHARMA and United Family Healthcare "completely part ways" | Quick announcement.

① FOSUN PHARMA's subsidiary plans to sell a 6.6% stake in the symbol company for 0.124 billion USD; ② The relationship between FOSUN PHARMA and Huameijia can be traced back to 2009; ③ After this Trade is completed, FOSUN PHARMA will completely exit Huameijia.

cls.cnMar 13 11:26 ET

Two Sessions Time | National People's Congress Representative, Lu Qingguo from Chenguang Biotech Group: Improve the quality standards of Chinese Patent Medicine, regulate the centralized procurement model for Traditional Chinese Medicine, and optimize the

① Lu Qingguo, Director of Chenguang Biotech Group and a representative of the National People's Congress, focused on several recommendations at this year's Two Sessions, including optimizing the procurement mechanism for Traditional Chinese Medicine, enhancing the quality standards for Chinese Patent Medicine, and standardizing the Traditional Chinese Medicine granule industry; ② In addition to recommendations related to the Traditional Chinese Medicine industry, Lu Qingguo prepared several suggestions on rural social retirement insurance, rural medical insurance, and increasing support for companies sanctioned by the United States.

cls.cnMar 2 21:09 ET

It was reported that FOSUN PHARMA will sell its Indian pharmaceutical company, and it stated that it will continue to promote the development of the Indian company in the Global market.

① It is rumored that FOSUN PHARMA will sell its pharmaceutical company Gland Pharma located in India, and the company stated it will continue to promote Gland Pharma's development and growth in the Global market. ② Previously, FOSUN PHARMA had reduced its Shareholding in Gland Pharma to supplement working capital, repay interest-bearing debts, and so on.

cls.cnFeb 20 18:46 ET